[Brief overview on the studies of monoclonal antibody].
There have been many basic and clinical reports of monoclonal antibody therapies of cancer, but most of them were in the phase I or early phase II. However, from these experiences, monoclonal antibody therapies have changed considerably using chimera or humanized antibodies. Recent reports on monoclonal therapies indicated the clinical usefulness in cancer treatment, opening a new era of biological therapies. Since there are no similar issues to cover so widely monoclonal antibody, this special issue will be useful for understanding the progress of monoclonal therapies.
Tsukagoshi
Shigeru
S
Cancer Institute, Japanese Foundation for Cancer Research.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins